2012 Q4 Form 10-Q Financial Statement
#000110465912074445 Filed on November 06, 2012
Income Statement
| Concept | 2012 Q4 | 2012 Q3 | 2011 Q3 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.360M |
| YoY Change | -100.0% | -93.97% | |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $5.850M | $5.380M | $5.080M |
| YoY Change | -3.94% | 5.91% | -8.14% |
| % of Gross Profit | |||
| Research & Development | $19.76M | $20.19M | $17.32M |
| YoY Change | -0.3% | 16.57% | 5.65% |
| % of Gross Profit | |||
| Depreciation & Amortization | $630.0K | $640.0K | $510.0K |
| YoY Change | 18.87% | 25.49% | 59.37% |
| % of Gross Profit | |||
| Operating Expenses | $25.62M | $20.19M | $17.32M |
| YoY Change | -1.12% | 16.57% | -21.0% |
| Operating Profit | -$25.57M | -$18.04M | |
| YoY Change | 41.73% | -135.83% | |
| Interest Expense | $140.0K | $110.0K | $4.000K |
| YoY Change | 16.67% | 2650.0% | -73.33% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$25.47M | -$25.46M | -$17.93M |
| YoY Change | -1.24% | 42.0% | -135.55% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$25.47M | -$25.46M | -$17.93M |
| YoY Change | -1.24% | 42.0% | -135.55% |
| Net Earnings / Revenue | -411.24% | ||
| Basic Earnings Per Share | -$0.36 | -$0.25 | |
| Diluted Earnings Per Share | -$298.7K | -$0.36 | -$0.25 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 87.00M shares | 71.64M shares | 71.23M shares |
| Diluted Shares Outstanding | 71.64M shares | 71.23M shares |
Balance Sheet
| Concept | 2012 Q4 | 2012 Q3 | 2011 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $298.2M | $183.9M | $265.7M |
| YoY Change | 20.43% | -30.79% | 58.63% |
| Cash & Equivalents | $33.48M | $26.80M | $18.68M |
| Short-Term Investments | $264.8M | $157.1M | $247.0M |
| Other Short-Term Assets | $4.200M | $2.700M | $2.900M |
| YoY Change | 61.54% | -6.9% | 31.82% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $302.5M | $186.6M | $268.6M |
| YoY Change | 20.87% | -30.52% | 37.95% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $5.826M | $5.861M | $5.223M |
| YoY Change | 19.34% | 12.22% | 30.58% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.759M | $1.826M | $2.050M |
| YoY Change | -11.65% | -10.93% | -10.87% |
| Total Long-Term Assets | $7.585M | $7.687M | $7.273M |
| YoY Change | 10.36% | 5.69% | 15.44% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $302.5M | $186.6M | $268.6M |
| Total Long-Term Assets | $7.585M | $7.687M | $7.273M |
| Total Assets | $310.0M | $194.3M | $275.9M |
| YoY Change | 20.59% | -29.56% | 37.25% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.697M | $1.388M | $1.275M |
| YoY Change | 9.06% | 8.86% | -57.5% |
| Accrued Expenses | $9.800M | $8.700M | $7.000M |
| YoY Change | 0.0% | 24.29% | -23.08% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $100.0K | ||
| YoY Change | -88.89% | ||
| Total Short-Term Liabilities | $12.20M | $10.59M | $8.422M |
| YoY Change | 5.87% | 25.68% | -34.71% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $96.00K | $102.0K | $123.0K |
| YoY Change | -17.95% | -17.07% | -98.63% |
| Total Long-Term Liabilities | $96.00K | $102.0K | $123.0K |
| YoY Change | -17.95% | -17.07% | -98.66% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $12.20M | $10.59M | $8.422M |
| Total Long-Term Liabilities | $96.00K | $102.0K | $123.0K |
| Total Liabilities | $12.30M | $10.69M | $8.545M |
| YoY Change | 5.63% | 25.07% | -61.33% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$760.2M | -$734.8M | -$635.6M |
| YoY Change | 14.94% | 15.6% | |
| Common Stock | $1.049B | $909.5M | $893.6M |
| YoY Change | 16.9% | 1.78% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $289.1M | $174.8M | $258.0M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $310.0M | $194.3M | $275.9M |
| YoY Change | 20.59% | -29.56% | 37.25% |
Cashflow Statement
| Concept | 2012 Q4 | 2012 Q3 | 2011 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$25.47M | -$25.46M | -$17.93M |
| YoY Change | -1.24% | 42.0% | -135.55% |
| Depreciation, Depletion And Amortization | $630.0K | $640.0K | $510.0K |
| YoY Change | 18.87% | 25.49% | 59.37% |
| Cash From Operating Activities | -$21.57M | -$19.63M | -$12.79M |
| YoY Change | 15.59% | 53.48% | -32.68% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$600.0K | -$390.0K | -$560.0K |
| YoY Change | 233.33% | -30.36% | -37.08% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$107.7M | $19.46M | -$10.94M |
| YoY Change | -697.5% | -277.88% | -212.09% |
| Cash From Investing Activities | -$108.3M | $19.08M | -$11.49M |
| YoY Change | -707.23% | -266.06% | -229.54% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 136.5M | 1.200M | 20.00K |
| YoY Change | 17629.87% | 5900.0% | -150.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -21.57M | -19.63M | -12.79M |
| Cash From Investing Activities | -108.3M | 19.08M | -11.49M |
| Cash From Financing Activities | 136.5M | 1.200M | 20.00K |
| Net Change In Cash | 6.680M | 650.0K | -24.26M |
| YoY Change | -11233.33% | -102.68% | 138.54% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$21.57M | -$19.63M | -$12.79M |
| Capital Expenditures | -$600.0K | -$390.0K | -$560.0K |
| Free Cash Flow | -$20.97M | -$19.24M | -$12.23M |
| YoY Change | 13.47% | 57.32% | -32.47% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2118000 | USD | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.03 | ||
| CY2011Q3 | us-gaap |
Contracts Revenue
ContractsRevenue
|
4355000 | USD |
| CY2011Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
17316000 | USD |
| CY2011Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5080000 | USD |
| CY2011Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
22396000 | USD |
| CY2011Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18041000 | USD |
| CY2011Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
114000 | USD |
| CY2011Q3 | us-gaap |
Interest Expense
InterestExpense
|
4000 | USD |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17931000 | USD |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.25 | |
| CY2011Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.25 | |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
71226000 | shares |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
71226000 | shares |
| us-gaap |
Contracts Revenue
ContractsRevenue
|
4750000 | USD | |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
49531000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
15677000 | USD | |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
65208000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-60458000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
294000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
22000 | USD | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-60186000 | USD | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.99 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.99 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
60660000 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
60660000 | shares | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1429000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10127000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
279000 | USD | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-185000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-128000 | USD | |
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-294000 | USD | |
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-1861000 | USD | |
| rigl |
Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
|
-286000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-50721000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
312622000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
234056000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-80684000 | USD | |
| us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
666000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
141876000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
141210000 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
9805000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
20000 | USD | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">              </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">Nature of Operations</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We were incorporated in the state of Delaware on June 14, 1996. We are engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">              </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended, (the Securities Act). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include all normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet at December 31, 2011 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2011.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12017000 | shares | |
| CY2012Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3245000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9354000 | USD | |
| CY2011Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3090000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10127000 | USD | |
| CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
26801000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
|
8 | item |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-63638000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
69237000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2569000 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
8168000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
282813000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
354826000 | USD | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-165000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-168000 | USD | |
| dei |
Entity Registrant Name
EntityRegistrantName
|
RIGEL PHARMACEUTICALS INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001034842 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-09-30 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| CY2012Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
71636000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
71505000 | shares | |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.03 | ||
| CY2012Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13822000 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13832000 | shares | |
| CY2011Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12017000 | shares |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1797000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9354000 | USD | |
| CY2012Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
71636000 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
71505000 | shares | |
| CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
25569000 | USD |
| us-gaap |
Contracts Revenue
ContractsRevenue
|
2250000 | USD | |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
76011000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-73761000 | USD | |
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2593000 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
250233000 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4882000 | USD |
| CY2011Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1991000 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
257106000 | USD |
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1556000 | USD |
| CY2011Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7271000 | USD |
| CY2011Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2571000 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
129000 | USD |
| CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
11527000 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
9313000 | USD |
| CY2011Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
117000 | USD |
| CY2012Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2011Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
100000 | USD | |
| CY2011Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18013000 | USD |
| CY2012Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2011Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
71000 | USD |
| CY2011Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
897479000 | USD |
| CY2011Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
6000 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-661407000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
236149000 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
257106000 | USD |
| CY2012Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2012Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
71379052 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
71379052 | shares |
| CY2012Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
71760104 | shares |
| CY2012Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
71760104 | shares |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8877000 | USD |
| CY2011Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18682000 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-25456000 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-73368000 | USD | |
| CY2009Q1 | rigl |
Loss Contingency Number Of Lawsuits Consolidated Into Single Action
LossContingencyNumberOfLawsuitsConsolidatedIntoSingleAction
|
2 | item |
| CY2012Q3 | us-gaap |
Assets Current
AssetsCurrent
|
186629000 | USD |
| CY2012Q3 | us-gaap |
Assets
Assets
|
194316000 | USD |
| CY2012Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10585000 | USD |
| CY2012Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
174804000 | USD |
| CY2012Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
194316000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
157094000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
229007000 | USD |
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
|
174475000 | USD |
| CY2011Q4 | rigl |
Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
|
235001000 | USD |
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
|
121000 | USD |
| CY2011Q4 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
|
76000 | USD |
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
|
15000 | USD |
| CY2011Q4 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
|
70000 | USD |
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
|
149010000 | USD |
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
|
34769000 | USD |
| rigl |
Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
|
P207D | ||
| rigl |
Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than
AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThan
|
P1Y | ||
| CY2012Q3 | rigl |
Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
|
174581000 | USD |
| CY2011Q4 | rigl |
Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
|
235007000 | USD |
| CY2012Q3 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
531000 | USD |
| CY2012Q3 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
8825000 | USD |
| CY2012Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
102000 | USD |
| CY2012Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2012Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
87000253 | shares |
| CY2012Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2734000 | USD |
| CY2012Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5861000 | USD |
| CY2012Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1826000 | USD |
| CY2012Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1388000 | USD |
| CY2012Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5399000 | USD |
| CY2012Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3267000 | USD |
| CY2012Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
72000 | USD |
| CY2012Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
909401000 | USD |
| CY2012Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
106000 | USD |
| CY2012Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-734775000 | USD |
| CY2012Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
20186000 | USD |
| CY2012Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5383000 | USD |
| CY2012Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
113000 | USD |
| CY2012Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-25569000 | USD |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
59014000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
16997000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
393000 | USD | |
| CY2012Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
69000 | USD |
| CY2011Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-82000 | USD |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
16000 | USD | |
| CY2012Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-25387000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-73268000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-60170000 | USD | |
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1872000 | USD | |
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
696000 | USD | |
| rigl |
Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
|
101000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2776000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2569000 | USD | |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18633000 | USD |
| CY2012Q3 | rigl |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
|
183895000 | USD |
| CY2011Q4 | rigl |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
|
247640000 | USD |
| CY2012Q2 | rigl |
Common Stock Shares Authorized Before Amendment
CommonStockSharesAuthorizedBeforeAmendment
|
100000000 | shares |
| rigl |
Collaborative Arrangement Maximum Period For Upfront Payment From Agreement Date
CollaborativeArrangementMaximumPeriodForUpfrontPaymentFromAgreementDate
|
P12M |
